Fundamental Analysis of ACRIVON THERAPEUTICS INC(NASDAQ:ACRV) stock

Fundamental Rating

Taking everything into account, ACRV scores 3 out of 10 in our fundamental rating. ACRV was compared to 568 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ACRV as it has an excellent financial health rating, but there are worries on the profitability. ACRV has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

ACRV had negative earnings in the past year.

In the past year ACRV has reported a negative cash flow from operations.

1.2 Ratios

ACRV has a better Return On Assets (-35.86%) than 61.95% of its industry peers.

Looking at the Return On Equity, with a value of -39.10%, ACRV is in the better half of the industry, outperforming 73.10% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-35.86%
ROE	-39.1%
ROIC	N/A

ROA(3y)-25.37%

ROA(5y)N/A

ROE(3y)-28.19%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ACRV does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The number of shares outstanding for ACRV has been increased compared to 1 year ago.

ACRV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

An Altman-Z score of 5.55 indicates that ACRV is not in any danger for bankruptcy at the moment.

With an excellent Altman-Z score value of 5.55, ACRV belongs to the best of the industry, outperforming 81.59% of the companies in the same industry.

There is no outstanding debt for ACRV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	5.55

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

ACRV has a Current Ratio of 12.75. This indicates that ACRV is financially healthy and has no problem in meeting its short term obligations.

ACRV has a Current ratio of 12.75. This is amongst the best in the industry. ACRV outperforms 86.19% of its industry peers.

ACRV has a Quick Ratio of 12.75. This indicates that ACRV is financially healthy and has no problem in meeting its short term obligations.

The Quick ratio of ACRV (12.75) is better than 86.37% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	12.75
Quick Ratio	12.75

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ACRV shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -1.12%.

EPS 1Y (TTM)-1.12%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%10.61%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

ACRV is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -1.58% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y5.85%

EPS Next 2Y-2.6%

EPS Next 3Y-1.31%

EPS Next 5Y-1.58%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ACRV. In the last year negative earnings were reported.

Also next year ACRV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-2.6%

EPS Next 3Y-1.31%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ACRV!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ACRIVON THERAPEUTICS INC

NASDAQ:ACRV (12/20/2024, 8:00:00 PM)

After market: 6.71 0 (0%)

6.71

+0.02 (+0.3%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-13 2024-11-13/bmo

Earnings (Next)N/A N/A

Inst Owners58.57%

Inst Owner Change-2.09%

Ins Owners9.96%

Ins Owner Change-3.1%

Market Cap208.95M

Analysts82.5

Price Target21.99 (227.72%)

Short Float %5.89%

Short Ratio19.5

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)7.6%

Min EPS beat(2)-0.13%

Max EPS beat(2)15.33%

EPS beat(4)2

Avg EPS beat(4)3.62%

Min EPS beat(4)-15.99%

Max EPS beat(4)15.33%

EPS beat(8)6

Avg EPS beat(8)7.7%

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-0.51%

PT rev (3m)-2.02%

EPS NQ rev (1m)-10.77%

EPS NQ rev (3m)-10.77%

EPS NY rev (1m)-3.55%

EPS NY rev (3m)-3.55%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	1.06
P/tB	1.06
EV/EBITDA	N/A

EPS(TTM)-2.7

EYN/A

EPS(NY)-2.87

Fwd EYN/A

FCF(TTM)-2.05

FCFYN/A

OCF(TTM)-1.95

OCFYN/A

SpS0

BVpS6.32

TBVpS6.32

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-35.86%
ROE	-39.1%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-25.37%

ROA(5y)N/A

ROE(3y)-28.19%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	363.84%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	12.75
Quick Ratio	12.75
Altman-Z	5.55

F-Score4

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)481.03%

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-1.12%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%10.61%

EPS Next Y5.85%

EPS Next 2Y-2.6%

EPS Next 3Y-1.31%

EPS Next 5Y-1.58%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-52.32%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-36.05%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-41.57%

OCF growth 3YN/A

OCF growth 5YN/A

ACRIVON THERAPEUTICS INC (ACRV)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens